Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 01, 2019 07:30 ET | Source: Biogen Inc.

Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients

New results from the NURTURE study demonstrate that pre-symptomatic infants treated with SPINRAZA are achieving motor milestones that are unprecedented in the natural history of the disease, including...
June 29, 2019 04:00 ET | Source: Biogen Inc.

Biogen announces European label update for SPINRAZA (nusinersen) which includes longer-term data across a broad range of ages and types of Spinal Muscular Atrophy

Label update includes data from four clinical studies including long-term safety and efficacy data across a broad Spinal Muscular Atrophy (SMA) populationData from over 300 patients across a broad...
June 11, 2019 19:05 ET | Source: Biogen Inc.

Biogen to Present New Safety and Efficacy Data on Biosimilars and Estimates 1.8 Billion Euros in Savings for the European Healthcare System in 2019

Data to be presented at the European Congress of Rheumatology (EULAR) 2019 highlight real-world evidence confirming the safety and efficacy of anti-TNF biosimilars and high adherence of patients to...
June 07, 2019 05:41 ET | Source: Biogen Inc.

Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Million

CAMBRIDGE, Mass., June 07, 2019 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) today announced that it has completed its acquisition of Nightstar Therapeutics (NST; Nasdaq: NITE), a clinical-stage gene...
May 30, 2019 07:30 ET | Source: Biogen Inc.

New Phase 3 Interim Results Support Safety and Efficacy of Diroximel Fumarate in Multiple Sclerosis

Diroximel fumarate significantly reduced disease activity in newly diagnosed relapsing multiple sclerosis (MS) patients and those previously treated with interferons or glatiramer acetate Data show...
May 20, 2019 07:30 ET | Source: Biogen Inc.

Biogen Recommends Stockholders Reject the Below-market Mini-tender Offer by TRC Capital Corporation

CAMBRIDGE, Mass., May 20, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Corporation (TRC Capital)...
May 14, 2019 19:02 ET | Source: Biogen Inc.

Biogen’s SPINRAZA® (nusinersen) Receives Positive Recommendation from NICE for Funding in the United Kingdom for the Treatment of Infants, Children and Adults with Spinal Muscular Atrophy

SPINRAZA becomes the first therapy recommended in the United Kingdom for 5q spinal muscular atrophy to treat all age groups, including patients who are pre-symptomaticMore than 7,500 individuals have...
May 07, 2019 07:30 ET | Source: Biogen Inc.

Data at AAN Demonstrate Biogen’s Leadership and Commitment to Innovation in MS

Updated results support lower risk of PML with extended interval dosing (EID; approximately every six weeks) for TYSABRI® (natalizumab) in patients in a real-world setting New interim data further...
May 06, 2019 07:30 ET | Source: Biogen Inc.

Biogen Presents Data at 2019 AAN Annual Meeting Affirming Longer-Term Safety and Durability of Treatment with SPINRAZA® (nusinersen)

Treatment with SPINRAZA resulted in clinically meaningful improvements in motor-function and survival in individuals with spinal muscular atrophyTreating pre-symptomatic infants with SPINRAZA helped...
May 01, 2019 16:30 ET | Source: Biogen Inc.

Biogen to Present New Interim Data from Its Phase 1/2 Clinical Study of Tofersen (BIIB067) for the Potential Treatment of a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS)

Tofersen, an antisense oligonucleotide (ASO) that selectively targets the genetic driver of disease, is being studied for the potential treatment of ALS in adults with a confirmed superoxide dismutase...